Point72 Asset Management L.P. increased its stake in GlaxoSmithKline plc (NYSE:GSK) by 504.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 604,419 shares of the pharmaceutical company’s stock after acquiring an additional 504,419 shares during the period. Point72 Asset Management L.P.’s holdings in GlaxoSmithKline were worth $24,539,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GSK. Proficio Capital Partners LLC lifted its position in GlaxoSmithKline by 16.1% during the second quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after buying an additional 457 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in GlaxoSmithKline by 1.9% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after buying an additional 64 shares in the last quarter. FTB Advisors Inc. lifted its position in GlaxoSmithKline by 16.9% during the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after buying an additional 539 shares in the last quarter. Quadrant Capital Group LLC lifted its position in GlaxoSmithKline by 3.5% during the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after buying an additional 148 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in GlaxoSmithKline by 93.4% during the second quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after buying an additional 1,955 shares in the last quarter. 9.83% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have weighed in on the stock. Cowen set a $38.00 price target on shares of GlaxoSmithKline and gave the company a “hold” rating in a research report on Monday. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, September 21st. Argus reduced their price target on shares of GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a research report on Thursday, November 30th. Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, Investec cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $39.37.

In other news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.00% of the company’s stock.

Shares of GlaxoSmithKline plc (GSK) opened at $35.58 on Thursday. The stock has a market cap of $87,356.00, a P/E ratio of 12.60, a PEG ratio of 1.97 and a beta of 0.98. GlaxoSmithKline plc has a 12 month low of $34.52 and a 12 month high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be paid a dividend of $0.5037 per share. The ex-dividend date is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.66%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio (DPR) is currently 163.12%.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline plc (GSK) Shares Bought by Point72 Asset Management L.P.” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.watchlistnews.com/glaxosmithkline-plc-gsk-shares-bought-by-point72-asset-management-l-p/1763503.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with Analyst Ratings Network's FREE daily email newsletter.